Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Vemurafenib + Cobimetinib
Treatment for Malignant skin melanoma
Typical Dosage: Vemurafenib 960mg orally twice daily + Cobimetinib 60mg orally once daily (21 days on, 7 days off)
Effectiveness
90%
Safety Score
38%
Clinical Trials
8
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
38
DangerousModerateSafe
Treatment Details
Dosage Range
Vemurafenib 960mg orally twice daily + Cobimetinib 60mg orally once daily (21 days on, 7 days off)
Time to Effect
1-2 months
Treatment Duration
1-2 years
Evidence Quality
HIGHConfidence Score
92%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$300,000
Monitoring:$12,000
Side Effect Mgmt:$10,000
Total Annual:$322,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$210,000/QALY
QALYs Gained
2.5
Outcome-Based Costs
Cost per Responder
$495,385
Cost per Remission
$2,146,667
Comparison vs Dabrafenib + Trametinib
Cost Difference
$-20,000/year
Less expensive
QALY Difference
0.00 QALYs
Same outcomes
Dominance
No dominance
Vemurafenib + Cobimetinib Outcomes
for Malignant skin melanoma
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+65%
Remission Rate
+15%
Common Side Effects
Dermatological (rash, photosensitivity)
+50%
Diarrhea
+45%
Nausea
+35%
Fatigue
+35%
Pyrexia
+35%
Arthralgia
+25%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
1 active trial recruiting for Vemurafenib + Cobimetinib in Malignant skin melanoma
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
NCT05768178RECRUITINGPHASE2, PHASE3
30 participants
INTERVENTIONAL
Belfast, United Kingdom +15 more
Started: Mar 1, 2023
Completed Clinical Trials
5 completed trials for Vemurafenib + Cobimetinib in Malignant skin melanoma
A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma
NCT01271803COMPLETEDPHASE1
131 participants
INTERVENTIONAL
Los Angeles, United States +9 more
Started: Feb 17, 2011
A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma
NCT01689519COMPLETEDPHASE3
495 participants
INTERVENTIONAL
Birmingham, United States +155 more
Started: Jan 8, 2013
Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis
NCT02537600COMPLETEDPHASE2
43 participants
INTERVENTIONAL
Bordeaux, France +16 more
Started: Dec 1, 2015
A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma
NCT01656642COMPLETEDPHASE1
67 participants
INTERVENTIONAL
Los Angeles, United States +7 more
Started: Aug 13, 2012
Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
NCT02902029COMPLETEDPHASE2
186 participants
INTERVENTIONAL
Boulogne-Billancourt, France +26 more
Started: Nov 1, 2016